21st week of 2010 patent applcation highlights part 47 |
Patent application number | Title | Published |
20100130533 | PHARMACEUTICAL CREAMS WITH REFINED OLEIC ACID - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-27 |
20100130534 | METHODS FOR REDUCING IMIQUIMOD IMPURITIES FOR TWO MONTHS, FOUR MONTHS, AND SIX MONTHS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-27 |
20100130535 | METHODS FOR STABILIZING IMIQUIMOD FOR TWO MONTHS, FOUR MONTHS, AND SIX MONTHS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-27 |
20100130536 | METHODS FOR CONTROLLING FORMATION OF IMIQUIMOD IMPURITIES FOR TWO MONTHS, FOUR MONTHS, AND SIX MONTHS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-27 |
20100130537 | CINNAMIDE COMPOUNDS FOR DEMENTIA - The invention provides methods for treating, preventing, and delaying the onset of dementia and mild cognitive impairments by administering to a patient in need thereof at least one cinnamide compound and one or more second-line active ingredients, such as cholinesterase inhibitors; AMPA receptor antagonists; NMDA receptor antagonists; and the like. The invention also provides pharmaceutical compositions, combinations, and kits. | 2010-05-27 |
20100130538 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF - The present invention provides a compound represented by the formula | 2010-05-27 |
20100130539 | IMIDAZOPYRIDINE INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein Q, X | 2010-05-27 |
20100130540 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF - The present invention provides compounds and methods for treating or preventing the development of a disease, disorder, or condition in a subject or patient. | 2010-05-27 |
20100130541 | Processes for the preparation of clopidogrel - The invention relates to processes for the preparation of clopidogrel and salts thereof. The inventors have developed a process for preparing racemic clopidogrel by racemizing R(−) clopidogrel. The process includes the step of reacting R(−) clopidogrel with a powered anhydrous base in one or more solvents. | 2010-05-27 |
20100130542 | Composition Comprising a Combination of Omeprazole and Lansoprazole, and a Buffering Agent, and Methods of Using Same - The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and sodium bicarbonate. Methods of using such compositions are also provided | 2010-05-27 |
20100130543 | PYRAZOLE CARBOXAMIDE INHIBITORS OF FACTOR XA - The present invention relates to new pyrazole carboxamide inhibitors of factor Xa, pharmaceutical compositions thereof, and methods of use thereof. | 2010-05-27 |
20100130544 | USE OF PARASYMPATHOLYTIC SUBSTANCES TO ENHANCE AND ACCELERATE STEM CELL DIFFERENTIATION, RELATED METHODS AND COMPOSITIONS - The invention refers to the in vitro and in vivo use of parasympatholytic substances, preferably scopolamine, to potentiate and accelerate the differentiation of stem cells into cells with a tissue-specific phenotype, and the process and compositions related thereto. | 2010-05-27 |
20100130545 | BRIDGED SIX-MEMBERED RING COMPOUNDS - The invention relates to compounds of formula (I), wherein R | 2010-05-27 |
20100130546 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a quinolone compound represented by General Formula (1) | 2010-05-27 |
20100130547 | SOLID FORMS OF N-(4-(7-AZABICYCLO[2.2.1]HEPTAN-7-YL)-2-(TRIFLUORORMETHYL)PHENYL)-4-OXO-5- -(TRIFLUOROMETHYL)-1,4-DIHYROQUINOLINE-3-CARBOXAMIDE - The present invention relates to solid state forms, for example, crystalline forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, pharmaceutical compositions thereof, and methods therewith. | 2010-05-27 |
20100130548 | BIPHENYL DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS - Biphenyl derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions. | 2010-05-27 |
20100130549 | PSYCHOTROPIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention provides a method for treating or preventing a disease or disorder treatable by the inhibition of serotonin reuptake in a patient, and/or norepinephrine reuptake and/or dopamine reuptake in a patient, the method comprising administering to the patient a neurotransmitter reuptake inhibiting-effective amount of at least one compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogean halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR | 2010-05-27 |
20100130550 | OCULAR FORMULATIONS OF NORKETOTIFEN - Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen. | 2010-05-27 |
20100130551 | Sufentanil Solid Dosage Forms Comprising Oxygen Scavengers and Methods of Using the Same - Compositions and methods effective to minimize or eliminate the presence of oxidative degradation products in solid dosage forms comprising sufentanil are provided. | 2010-05-27 |
20100130552 | Therapeutic Agents Useful for Treating Pain - A compound of Formula: (I) or a pharmaceutically acceptable derivative thereof, where Ar | 2010-05-27 |
20100130553 | USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDIN-4-YL)-5-(MET- HOXY)PYRIDINE-2-CARBOXAMIDE IN THE TREATMENT OF CRANIAL TRAUMAS - The invention relates to the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the preparation of a medicament for use in the treatment of cerebral traumas. | 2010-05-27 |
20100130554 | USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOX- Y)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE - The present invention relates to the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in the form of a hydrate, of a solvate, of a base or of an addition salt with an acid, for preparing a medicament for use in the treatment of motor disorders related to Parkinson's disease. | 2010-05-27 |
20100130555 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY - A method for treating or preventing injury of a biological material exposed to hypoxic or ischemic conditions comprising contacting the biological material with an effective amount of a compound is disclosed. The compound has the following structure (I): | 2010-05-27 |
20100130556 | EP2 RECEPTOR AGONISTS - A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R | 2010-05-27 |
20100130557 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS - The present invention relates to substituted arylsulphonylglycines of general formula (I) wherein R, X, Y and Z are defined as in claim | 2010-05-27 |
20100130558 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS - The present application relates to calcium channel inhibitors containing compounds of formula (I) | 2010-05-27 |
20100130559 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE - The present invention relates to a compound represented by formula (I), which has a GPR120 agonist action and thus is useful for treatment of diabetes mellitus or hyperlipidemia, or a pharmaceutically acceptable salt thereof. In the formula, (AA) represents a phenyl or the like, which may be substituted with a lower alkoxy group or the like; (BB) represents a divalent group or the like, derived by removal of two hydrogen atoms from a benzene which may be substituted with a halogen atom or the like; X represents a spacer having a main chain composed of 1-8 carbon atoms wherein 1-3 carbon atoms in the main chain may be substituted with an oxygen atom or the like; and Y represents a hydrogen atom or the like. | 2010-05-27 |
20100130560 | FUNGICIDE 2-PYRIDYL-METHYLENE-THIO CARBOXAMIDE OR 2-PYRIDYL-METHYLENE-N-SUBSTITUTED CARBOXIMIDAMIDE DERIVATIVES - The present invention relates 2-pyridyl-methylene-thiocarboxamide or 2-pyridyl-methylene-N-substituted-carboximidamide derivatives of formula (I) wherein A represents a carbo-linked 5-membered heterocyclyl group; T represents S, N—R | 2010-05-27 |
20100130561 | CONTROLLING PESTS BY COMBINING INSECTICIDES AND TRANSGENIC PLANTS BY APPLYING DIRECTLY TO LEAVES AND ROOTS - The invention relates to a method for controlling pests using a combination of insecticides and transgenic plants and consequently improving the utilization of the production potential of transgenic plants which comprises treating the plant with active compound combinations comprising an active compound from the group of the anthranilamides and at least one further insecticide. | 2010-05-27 |
20100130562 | Stabilized Nicotine Chewing Gum - A nicotine chewing gum composition with improved stability. | 2010-05-27 |
20100130563 | INHIBITORS OF PLASMA KALLIKREIN - The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment. | 2010-05-27 |
20100130564 | SMALL MOLECULE INHIBITORS OF BCL6 - Provided are methods of inhibiting BCL6 repression in a mammalian cell. Also provided are methods of treating cancer in a mammal. | 2010-05-27 |
20100130565 | THIOAMIDE COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF - The present invention relates to novel thioamide derivatives of formula (I) and formula (Ia): | 2010-05-27 |
20100130566 | Treatment of autism spectrum disorders with agents that activate the Locus Coeruleus - Noradrenergic system - Methods are provided for treating autism spectrum disorders (ASD) using agents that activate the locus coeruleus-noradrenergic (LC-NA) system of the brain and for screening for compounds for treating ASD comprising determining whether or not the compounds activate the LC-NA system. | 2010-05-27 |
20100130567 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE - A method of treating or preventing Alzheimer's disease or mild cognitive impairment which is an early state of cognitive impairment including Alzheimers' disease by administering a pharmacologically effective amount of an angiotensin II receptor blocker. A method of improving cerebral circulation or cerebral blood flow disorder by administering a pharmacologically effective amount of an angiotensin II receptor blocker. A method of treating or preventing amyloid β-induced brain disfunction by administering a pharmacologically effective amount of an angiotensin II receptor blocker. | 2010-05-27 |
20100130568 | TOPICAL COMPOSITIONS COMPRISING TELMESTEINE FOR TREATING DERMATOLOGICAL DISORDERS - This invention relates to topical compositions, such as creams and lotions, that comprise or consist essentially of Telmesteine, or a pharmaceutically acceptable salt thereof, as the active ingredient, and methods for their use in treating a variety of dermatological diseases and disorders, including atopic, dermatitis (eczema), allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopy. | 2010-05-27 |
20100130569 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR POSTERIOR OCULAR DISEASE COMPRISING NON-ERGOT SELECTIVE D2 RECEPTOR AGONIST AS ACTIVE INGREDIENT - The invention provides a novel prophylactic or therapeutic agent for a posterior ocular disease. Pramipexole which is a non-ergot selective D | 2010-05-27 |
20100130570 | FUNGICIDE N-5-MEMBERED FUSED HETEROARYL-METHYLENE-N-CYCLOALKYL-CARBOXAMIDE DERIVATIVES - The present invention relates N-5-membered, fused, heteroaryl-methylene-N-cycloalkyl-carboxamide derivatives, their thiocarboxamide or N-substituted carboximidamide analogues, all of formula (I) wherein A represents a carbo-linked 5-membered heterocyclyl group; T represents O, S, N—R | 2010-05-27 |
20100130571 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF - The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a thiazolidinone compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a thiazolidinone compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a thiazolidinone compound to a non-human animal in an amount sufficient to inhibit CFTR. | 2010-05-27 |
20100130572 | CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE - The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization. | 2010-05-27 |
20100130573 | TREATMENT AND PREVENTION OF DELETERIOUS EFFECTS ASSOCIATED WITH ALCOHOL CONSUMPTION - The present invention provides to methods and compositions that treat or prevent deleterious effects associated with alcohol consumption including alcohol-induced flush reaction and hangover. The methods and compositions include famotidine and optionally succinic acid. The present invention further demonstrates compositions that include famotidine are effective at treating symptoms associated with a flush reaction in subjects that are not significantly responsive to treatments with the H1 antagonist loratidine or the H2 antagonist cimetidine. | 2010-05-27 |
20100130574 | NEURODEGENERATIVE DISEASES AND METHODS OF MODELING - This invention relates to methods for neuroprotection, promoting survival of motor neurons and the treatment of motor neuron diseases by preventing cell signaling through the classic prostaglandin D2 receptor DP1. | 2010-05-27 |
20100130575 | COMPOUND WITH ANESTHETICS ACTIVITY, METHODS FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - The present invention is related to a new series of chemical compounds, namely 3-benzyl-imidazolidine-2,4-dione substituted in the position 2 and/or 6 of benzyl ring by halogens as presented to the molecule named LPSF-PT-31, GIRSUPAN and its therapeutic use as drug with analgesic, sedative and adjuvant of anesthetics activities. The invention is also related to a process for production of said compounds as well as pharmaceutical compositions comprising them. | 2010-05-27 |
20100130576 | PHARMACEUTICAL COMPOSITION - To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. | 2010-05-27 |
20100130577 | PYRAZALONE DERIVATIVE FORMULATIONS - Pyrazolone derivative formulations are provided. The formulations include a pyrazolone derivative active agent, e.g., edaravone, and an amphiphilic solubilizing agent. Also provided are methods of making and using the subject formulations. | 2010-05-27 |
20100130578 | ACTIVE INGREDIENT COMBINATIONS HAVING INSECTICIDE AND ACARICIDE PROPERTIES - The new active compound combinations comprising compounds of the formula (I) and the active compounds (1) to (3) recited in the description possess very good insecticidal and/or acaricidal properties. | 2010-05-27 |
20100130579 | CANCER THERAPY - The present invention relates to methods of inducing expression of an epigenetically silenced gene, RASSF1A, in cells, particularly human cells, such as cancer cells. It also relates to methods of treating an individual, prophylactically or therapeutically, for cancer in which RASSF1A is epigenetically silenced. | 2010-05-27 |
20100130580 | Formulations and Methods for Treating Dry Eye - The present invention provides compositions comprising a low dose amount of an ophthalmic NSAID for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye and safe for chronic use. | 2010-05-27 |
20100130581 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN - This invention relates to derivatives of an endomorphin, or of an endomorphin analog, comprising at least one moiety selected from a lipid moiety, a cyclitol moiety and a saccharide moiety. | 2010-05-27 |
20100130582 | INDOLINONE MODULATORS OF DOPAMINE RECEPTOR - The present invention relates to new indolinone modulators of dopamine receptor, pharmaceutical compositions thereof, and methods of use thereof. | 2010-05-27 |
20100130583 | PROLINAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS - The invention relates to quaternary α-aminocarboxyamide derivatives of formula (I) and their pharmaceutically salts or solvates | 2010-05-27 |
20100130584 | NOVEL COMPOUNDS FROM ANTRODIA CAMPHORATA - Compounds isolated from the fruiting body of | 2010-05-27 |
20100130585 | METHODS AND COMPOSITIONS FOR INVESTIGATION AND TREATMENT OF CANCER USING A G-PROTEIN COUPLED EICOSANOID RECEPTOR - In some embodiments, without limitation, the present invention comprises compositions and methods for the investigation and treatment of cancers by directly or indirectly blocking or interfering with the delivery of survival signals in cancer cells via a G protein-coupled receptor, in some embodiments, a 5-oxoETE or 5-HETE receptor. Some embodiments comprise the receptor itself and methods to manipulate, block, or interfere with expression of or activity by or through binding with the receptor, including without limitation, by interference with, inhibition, or prevention of action by metabolites of arachidonate 5-lipoxygenase, such as 5-HETE and its derivative, 5-oxoETE. | 2010-05-27 |
20100130586 | DIAGNOSIS AND TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA - The present invention relates to the field of biotechnological means to diagnose or treat T-cell acute lymphoblastic leukaemia. More particularly, the invention relates to methods to diagnose T-cell acute lymphoblastic leukaemia via determining the presence of a duplication of the MYB gene in cells taken from patients. The invention further relates to inhibitors capable of neutralizing the biological activity of MYB alone, or in combination with inhibitors capable of neutralizing the biological activity of NOTCH1, which can be used to treat T-cell acute lymphoblastic leukaemia. | 2010-05-27 |
20100130587 | METHODS OF TREATING CANCER USING siRNA MOLECULES DIRECTED AGAINST CD24 - A method of treating a CD24-related medical condition is disclosed. The method comprises administering to a subject in need thereof at least one siRNA molecule selected from the group consisting of SEQ ID NO: 1 to 4. Pharmaceutical compositions comprising same are also disclosed. | 2010-05-27 |
20100130588 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY - The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP. | 2010-05-27 |
20100130589 | MODULATION OF eIF4E EXPRESSION - Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided. | 2010-05-27 |
20100130590 | DELETION BEARING BARD1 ISOFORMS AND USE THEREOF - The present invention relates to new protein isoforms, use thereof, methods of preparation thereof, methods of detection thereof, antibodies thereof, combination of antibodies thereof, use of these antibodies and combinations thereof and use of antagonists of those isoforms for the treatment of gynaecological cancers. | 2010-05-27 |
20100130591 | MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD - Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy. | 2010-05-27 |
20100130592 | RNA Interference Mediated Inhibition of GRB2 Associated Binding Protein (GAB2) Gene Expression Using Short Interfering Nucleic Acid (siNA) - This invention relates to compounds, compositions, and methods useful for modulating GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of GRB2 associated binding protein (GAB2) gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of GAB2 genes. The small nucleic acid molecules are useful in the treatment of cancer, malignant blood disease (leukemia), inflammatory diseases or conditions, allergic diseases or conditions, or proliferative diseases or conditions. | 2010-05-27 |
20100130593 | METHODS AND IMMUNE MODULATOR NUCLEIC ACID COMPOSITIONS FOR PREVENTING AND TREATING DISEASE - This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly the treatment and prevention of autoimmune or inflammatory diseases. The invention also relates to the treatment or prevention of disease comprising the administration of the immune modulatory nucleic acids alone or in combination with a polynucleotide encoding self-antigen(s), -proteins(s), -polypeptide(s) or -peptide(s). The present invention also relates to methods and compositions for treating diseases in a subject associated with one or more self-antigen(s), self-proteins(s), -polypeptide(s) or -peptide(s) that are present in the subject and involved in a non-physiological state. | 2010-05-27 |
20100130594 | CNS GENE DELIVERY USING PERIPHERAL ADMINISTRATION OF AAV VECTORS - The present invention relates to compositions and methods for the delivery of therapeutic proteins to the CNS using recombinant AAV vectors. More specifically, the invention relates to compositions and methods for delivering proteins into the cerebrospinal fluid of mammalian subjects through peripheral administration of AAV vectors. The invention may be used to treat various disorders of the central nervous system, including degenerative diseases and motor neuron diseases. | 2010-05-27 |
20100130595 | ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF - This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds. | 2010-05-27 |
20100130596 | RAD51 DERIVED CANCER CELL SPECIFIC PROMOTERS FOR TARGETED ANTI- CANCER THERAPY - Provided are compositions and methods for inhibiting growth of cancer cells. The method of the invention relates to delivering to cells an effective amount of a composition that contains a polynucleotide having a Rad51 promoter or a polynucleotide having at least 95% similarity to a Rad51 promoter. The Rad51 promoter is operably linked to a coding region for a cytotoxic agent. In vitro and in vivo results demonstrating effectiveness of the polynucleotides of the invention are presented. | 2010-05-27 |
20100130597 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION - The invention relates to new functions of the DNA-PKcs gene product in energy metabolism, brain function and physical fitness. | 2010-05-27 |
20100130598 | METHODS FOR INDUCING PROGRAMMED CELL DEATH - The present invention relates to methods for inducing or promoting caspase-independent apoptosis in a cell, the method comprising exposing to the cell an effective amount of a compound of formula I as described herein. The invention also relates to methods for treating or preventing diseases and disorders by administering to subjects in need thereof an effective amount of a compound of formula I, wherein the compound induces or promotes caspase-independent apoptosis in at least one cell of the subject. | 2010-05-27 |
20100130599 | CYP2C9*8 Alleles Correlate With Decreased Warfarin Metabolism And Increased Warfarin Sensitivity - The present disclosure is related to a method of identifying a subject with increased sensitivity to warfarin. The method includes identifying a CYP2C9*8 polymorphism in the subject, wherein the presence of said polymorphism is indicative of a patient with increased sensitivity to warfarin relative to a subject having the corresponding wild-type allele. | 2010-05-27 |
20100130600 | LIPOPROTEIN LIPASE AND ITS EFFECT ON STATIN TREATMENTS - The invention provides methods of treating and prognosing atherosclerosis and lipid response to statin treatment by determining the presence or absence of haplotypes at the lipoprotein lipase locus. In one embodiment, the invention is practiced by evaluating the prognosis of vascular grafts in an individual undergoing statin treatment by determining the presence or absence of haplotypes at the lipoprotein locus. | 2010-05-27 |
20100130601 | INSECTICIDAL COMPOUNDS - A compound of formula (I), wherein A | 2010-05-27 |
20100130602 | PESTICIDAL COMPOSITION AND METHOD FOR CONTROLLING HARMFUL INSECTS - A pesticidal composition containing: 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate, a saturated hydrocarbon having an initial boiling point of 150° C. or higher and a 95%-distillation temperature of 300° C. or lower, and at least one alkyl carboxylate ester selected from the group consisting of the following esters (i) to (iii): (i) alkyl alkylcarboxylate esters having 12 to 20 carbon atoms, (ii) dialkyl dicarboxylate esters having 12 to 20 carbon atoms, and (iii) trialkyl acetylcitrate esters having 12 to 20 carbon atoms; has an excellent pesticidal acivity. | 2010-05-27 |
20100130603 | MEDICAMENT FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF DERMATOSIS RESULTING FROM EXCESSIVELY ADVANCED KERATINIZATION - A medicament for prophylactic and/or therapeutic treatment of a dermatosis resulting from excessively advanced keratinization, such as non-hereditary inflammatory keratosis and hereditary congenital keratosis, which comprises a substance selected from the group consisting of a cannabinoid agonist and a vanilloid agonist as an active ingredient. | 2010-05-27 |
20100130604 | USE OF ROSMARINIC ACID IN MANUFACTURE OF MEDICAMENTS FOR TREATING OR PREVENTING HEPATIC AND RENAL DISEASES - The present invention demonstrates through many experiments that Rosmarinic acid (RA) can inhibit the expression of connective tissue growth factor (CTGF) and therefore is useful for the prevention or treatment of hepatofibrosis and nephrofibrosis. Based on this, the present invention provides novel uses of RA and pharmaceutical compositions comprising the same in the manufacture of medicaments useful for the prevention or treatment of chronic hepatitis, CRF, and diabetic nephropathy. | 2010-05-27 |
20100130605 | Use of Derivatives of Sinapinic Acid and Compositions Comprising Such Derivatives - The present invention relates to substances which can be used as cosmetic ingredients, especially for skin whitening and as cosmetic agents against signs of ageing skin. The present invention also relates to the use of such substances for the manufacture of a medicament for the treatment of disorders related to the pigmentation of the skin. The invention furthermore relates to specific substances. | 2010-05-27 |
20100130606 | PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE - The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation. | 2010-05-27 |
20100130607 | NEUROPROTECTION IN DEMYELINATING DISEASES - Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate. | 2010-05-27 |
20100130608 | COMPOSITIONS AND METHODS FOR REDUCING TRIGLYCERIDE LEVELS - The present invention is directed to methods of reducing plasma triglyceride level in subjects by administering docosahexaenoic acid (DHA). The method can comprise administering daily to the subject a dosage form comprising docosahexaenoic acid ester substantially free of eicosapentaenoic acid (EPA), wherein the DHA is derived from an algal source. In some embodiments, the method comprises administering daily to the subject a dosage form comprising DHA ester substantially free of EPA, wherein the DHA ester is about 60% to about 99.5% (w/w) of the total fatty acid content of the dosage form. In some embodiments, the method comprises administering daily to the subject a dosage form comprising about 200 mg to about 4 g of DHA ester substantially free of EPA. In some embodiments, the foregoing methods also result in a lowering of the amount of total cholesterol in the subject. | 2010-05-27 |
20100130609 | Ester of Hexyldecanol Having Short-Chained Fatty Acids - The present invention relates to the use of one or more esters of 2-hexyldeconal having fatty acids of the general formula (I) R1-COOH, wherein R1 is a linear or branched, saturated or unsaturated alkyl radical having 1 to 6 carbon atoms, in and/or for the production of cosmetic and/or pharmaceutical preparations. | 2010-05-27 |
20100130610 | DEODORIZATION AND STABILIZATION OF MARINE OILS - The invention relates to a process for the preparation of deodorized and stabilized food-grade marine oils by submitting marine oils to a counter-current steam distillation (CCSD) in a thin film column containing a structured packing and, if desired, adding antioxidant(s), to the food-grade marine oils thus obtained and to their uses in the food/feed, cosmetic and/or pharmaceutical industry. | 2010-05-27 |
20100130611 | OMEGA 3 FATTY ACID FORMULATIONS - The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof. | 2010-05-27 |
20100130612 | COMPOSITION CONTAINING CHITOSAN FOR SUSTAINED DRUG RELEASE - The present invention relates to a composition for sustained drug release, comprising chitosan dissolved in a solvent having a pH of below about 4.0, wherein the chitosan is selected from the group of chitosans precipitating in a pH range of between about 3.0 and about 7.5; and at least one drug compound soluble in the above chitosan solution. | 2010-05-27 |
20100130613 | ADMINISTRATION OF ADAPALENE FOR MODULATING THE EXPRESSION OF CD1d OR IL-10 - Adapalene or pharmaceutically acceptable salt thereof is administered to an individual in need of such treatment for modulating the expression of CD1d or IL-10 in an inflammatory acneic lesion. | 2010-05-27 |
20100130614 | ADMINISTRATION OF ADAPALENE FOR MODULATING THE EXPRESSION OF IL-1ra - Adapalene or pharmaceutically acceptable salt thereof is administered to an individual in need of such treatment for modulating the expression of IL-1ra by the cells of acneic epidermis. | 2010-05-27 |
20100130615 | SULFONYLUREA INHIBITORS OF ATP-SENSITIVE POTASSIUM CHANNELS - The present invention relates to new sulfonylurea inhibitors of ATP-sensitive potassium channels, pharmaceutical compositions thereof, and methods of use thereof. | 2010-05-27 |
20100130616 | SALT OF ALISKIREN WITH OROTIC ACID - The invention relates to a new salt of aliskiren, the respective production and usage, and pharmaceutical preparations containing such a salt. | 2010-05-27 |
20100130617 | ETHANOLAMINE MODULATORS OF NMDA RECEPTOR AND MUSCARINIC ACETYLCHOLINE RECEPTOR - The present invention relates to new ethanolamine modulators of NMDA receptors and/or muscarinic acetylcholine receptors, pharmaceutical compositions thereof, and methods of use thereof. | 2010-05-27 |
20100130618 | TREATMENT OF HUMAN DISEASE CONDITIONS AND DISORDERS USING VITAMIN K ANALOGUES AND DERIVATIVES - The present invention is related to the therapeutic uses of vitamin K, its analogues and derivatives in a diverse array of disease conditions. Vitamin K improves blood perfusion and ameliorates hypoxia in prevention and treatment of conditions such as chronic venous insufficiency manifestations, post thrombotic syndrome, skin conditions related to melanization, hyperpigmentation, Paresthesiae, oedema, varicose veins, VTE and cramps. The invention also provides pharmaceutical compositions comprising vitamin K, its analogues, derivatives or vitamin K-like compounds either alone or in combination with one or more therapeutically effective active agents for the diseases/conditions of venous, nerves and lymph, that are encompassed by this invention. | 2010-05-27 |
20100130619 | PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION OF IDEBENONE - The invention describes use of an injectable form of Idebenone, suitable for intravenous injection or infusion. The proposed formulation is an oil-in-water emulsion, where Idebenone is associated with the oil droplets. | 2010-05-27 |
20100130620 | NOVEL USE OF HYDROXYTYROSOL AND OLIVE EXTRACTS/CONCENTRATES CONTAINING IT - The present invention is directed to the use of (a composition comprising) hydroxytyrosol for treating or preventing age-related macular degeneration in humans, for maintaining the eye health in animals (preferably in humans), especially in elderly animals (preferably elderly humans), for improving the vision of animals (preferably of humans), for maintaining the high resolution vision in animals (preferably in humans) and/or for maintaining the visual acuity in animals (preferably in humans), as well as for maintaining the visual performance in animals (preferably in humans) and/or the visual function in animals (preferably in humans). | 2010-05-27 |
20100130621 | USE OF HYDROXYTYROSOL AS ANTI-AGING AGENT - The present invention is directed to the use of (a composition comprising) hydroxytyrosol as anti-aging agent. The composition, to which the present invention is also directed, does essentially not comprise resveratrol and is administered orally to animals. The present invention is further directed to anti-aging methods. “Anti-aging” meaning in the context of the present invention: retarding the aging processes in said animals, improving age-related physiological deficits in said animals and/or promoting a healthy aging in said animals. | 2010-05-27 |
20100130622 | PHARMACEUTICAL PREPARATION FOR PREVENTING AND/OR TREATING PERIODONTAL DISEASE, AGENT FOR ORAL HYGIENE COMPRISING THEREOF, AND FOOD COMPRISING THEREOF - The present invention provides a pharmaceutical composition for preventing and/or treating periodontal disease comprising at least one having dental root-periodontal tissue formation promotion effect selected from the group consisting of a compound shown in a following formula (I). | 2010-05-27 |
20100130623 | PRODUCTION OF STILBENES IN PLANT HAIRY ROOT CULTURES AND OTHER ROOT CULTURES - Improved methods for production of stilbenoids including resveratrol, pinosylvin and their respective derivatives are provided, including producing root cultures from plant cells and eliciting production of the stilbenes. The plant cells in an embodiment are contacted with substances which elicit production of the stilbenoid compounds. | 2010-05-27 |
20100130624 | 4-ALKYL SUBSTITUTED PYRIDINES AS ODIFEROUS SUBSTANCES - The present invention primarily concerns certain 4-alkyl pyridines of the following formula (I), | 2010-05-27 |
20100130625 | PROTON EXCHANGE MEMBRANE AND METHOD FOR MANUFACTURING THE SAME - A proton exchange membrane and method for formation the same is disclosed. When forming the proton exchange membrane, first, a bismaleimide and barbituric acid are copolymerized to form a hyper-branched polymer. Next, the solvent of the sulfonated tetrafluorethylene copolymer (Nafion) aqueous solution is replaced with dimethyl acetamide (DMAc). 10 to 15 parts by weight of the hyper-branched polymer is added to 90 to 85 parts by weight of the Nafion in the DMAc solution, stood and heated to 50° C. for inter-penetration of the hyper-branched polymer and the Nafion. The heated solution is coated on a substrate, baked, and pre-treated to remove residue solvent to complete formation of the proton exchange membrane. | 2010-05-27 |
20100130626 | METHOD FOR MANUFACTURING ANION EXCHANGE RESIN, ANION EXCHANGE RESIN, METHOD FOR MANUFACTURING CATION EXCHANGE RESIN, CATION EXCHANGE RESIN, MIXED BED RESIN, AND METHOD FOR MANUFACTURING ULTRAPURE WATER FOR WASHING ELECTRONIC COMPONENT MATERIAL - A method for manufacturing an anion exchange resin, in which remaining of impurities and generation of decomposition products are suppressed and leachables are reduced, the method including the following steps (1-a) to (1-e) of: (1-a) obtaining a cross-linked copolymer by copolymerizing a monovinyl aromatic monomer and a cross-linkable aromatic monomer; (1-b) specifying the content of a specific leachable compound to be 400 μg or less relative to | 2010-05-27 |
20100130627 | PROCESS FOR THE PREPARATION OF GRANULES BASED ON EXPANDABLE THERMOPLASTIC POLYMERS AND RELATIVE PRODUCT - A process for the continuous production of granules based on thermoplastic polymers includes at least one expandable agent and, optionally, other polymers or additives, among which inorganic pigments insoluble in the polymeric matrix, wherein a first main stream is prepared, in the molten state, and a second stream in the molten state, which englobes the additives and which is added to the first stream. The mixture is extruded through a die which is cooled by means of water jets from nozzles positioned behind the cutting blades. | 2010-05-27 |
20100130628 | AROMATIC POLYIMIDE AND PROCESS FOR PRODUCTION THEREOF - Disclosed is an aromatic polyimide having extremely high stiffness and extremely high gas barrier property, which is prepared from a tetracarboxylic acid component consisting essentially of 25 mol % to 97 mol % of 3,3′,4,4′-biphenyltetracarboxylic acid and 75 mol % to 3 mol % of 4,4′-oxydiphthalic acid based on 100 mol % of the total amount of the tetracarboxylic acid component, and a diamine component consisting essentially of p-phenylenediamine. | 2010-05-27 |
20100130629 | CATALYST COMPOSITION FOR PRODUCTION OF POLYURETHANE RESIN AND METHOD FOR PRODUCING POLYURETHANE RESIN (AS AMENDED) - Disclosed is a catalyst composition for polyurethane resin production which contains (A) triethylenediamine, (B) a specific polyisocyanurating catalyst and/or (C) a specific highly temperature-sensitive catalyst. By using this catalyst composition, a polyurethane resin can be molded with good curability, while suppressing initial reactivity. Consequently, a polyurethane resin having excellent moldability and fluidity can be produced with high productivity by using the catalyst composition. The thus-obtained polyurethane resin is suitably applicable to shoe soles. The component (B) is selected from the group consisting of alkali metal salts of carboxylic acids, quaternary ammonium compounds expressed as R | 2010-05-27 |
20100130630 | PROCESS FOR PREPARING A TRIBLOCK COPOLYMER COMPRISING A SEMI-CRYSTALLINE AND/OR HYDROLYSABLE BLOCK, AN ELASTOMERIC BLOCK AND AN AMORPHOUS BLOCK - The invention relates to a process for the preparation of a block copolymer comprising a sequence successively comprising a semicrystalline and/or hydrolysable block, an elastomeric block and an amorphous block, comprising the following stages:
| 2010-05-27 |
20100130631 | POLYESTER POYOL COMPOSITION FOR RIGID POLYURETHANE FOAMS,AND RIGID POLYURETHANE FOAM - Polyester polyol compositions have a low viscosity and are suited for the production of rigid polyurethane foams. Compositions for rigid polyurethane foams contain the polyester polyol compositions. Rigid polyurethane foams are produced therefrom. | 2010-05-27 |
20100130632 | Closed Cell Foams Comprising Urethane Elastomers - Chemically blown polyurethane elastomeric closed cell foams which exhibit physical characteristics similar to those of neoprene foams are disclosed. The foams are prepared by blending a diisocyanate or polyisocyanate prepolymer, a polyol, such as a polyether polyol or polyester polyol, an amine catalyst, a chemical blowing agent, and optionally a C | 2010-05-27 |